Psychopharmacology

Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

Clinicians explore neuroscience-guided off-label prescribing.

Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.

Round on the latest news in psychiatry from the last week.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Bupropion may cause dose-linked tinnitus; this case shows symptoms improve after dose reduction, helping manage depression without stopping treatment.

Experts share more on research developments of remternetug for Alzheimer disease.

A pharma expert and clinician shares perspectives on developing treatments.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

Learn more about the history of pharmacogenomics.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

A relationship between inflammatory skin disease and depression revealed in new research.

A novel form of agomelatine shows positive initial results.

Phase 2 trial of oveporexton for narcolepsy type 1 finds improvement on measures of cognition, in addition to previously demonstrated improved hallmark symptom of nighttime wakefulness.

Psychiatry experts unpack why off-label medications are common and how evidence and dosing guide care.

Further data shared on LB-102 for schizophrenia.

Tazbentetol interim results show improvement in schizophrenia symptoms.